Our team recently completed a clinical trial tasked with measuring the efficacy of a dietary supplement as an intervention for adults with an elevated blood pressure, or stage I hypertension. By employing a hybrid study model, sustaining patient engagement, and reducing resources required of the patient and study team, we successfully beat the dropout allowance.
All clinical trials require resource consumption from both the study team and participant. The following infographic will detail the differences in resources required in the digital (hybrid) model compared to that of the traditional "brick and mortar" model.
Diversity in research studies is essential when conducting clinical investigations in the U.S. Learn how social media and digital clinical trials were used for recruiting participants in under-represented racial and
Digital patient-centric clinical trials (PCT) are often carried out in the hybrid setting (minimizing site visits and maximizing the use of a virtual site), or the site-less setting (solely using the virtual site). The pairing of a digitalized PCT with social media targeting increases the probability of successful enrollment.
ObvioHealth orchestrated an in-home observational study to measure infant crying and fussing captured via a recording device, compared with data gathered from parental e-diaries and daily questionnaires.
An international food manufacturer offering a line-up of well-known brands under the liquid condiment category planned to drive growth by introducing its legacy rice vinegar brand as an intervention to lower blood pressure in pre-hypertensive adults and those with an increased risk of CVD.
I’ve been involved in clinical research in the traditional “brick and mortar site” setting, and now, in my current role as a principal investigator (PI) for ObvioHealth, in the digital
Diversity in Clinical Trial Enrollment: Exploring the Roadblocks to Minority Participation in Clinical Research
n the first part of our two-piece series exploring minority participation in clinical trial research, we examine the numerous challenges to securing diversity in clinical trials, and the consequences of primarily white patient populations.